Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · IEX Real-Time Price · USD
12.40
+0.42 (3.51%)
At close: May 17, 2024, 4:00 PM
12.50
+0.10 (0.81%)
After-hours: May 17, 2024, 7:55 PM EDT

Precision BioSciences Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2017
Cash & Equivalents
116.68189.58143.6689.8180.89
Upgrade
Short-Term Investments
11.90000
Upgrade
Cash & Cash Equivalents
128.58189.58143.6689.8180.89
Upgrade
Cash Growth
-32.18%31.96%59.98%-50.36%75.29%
Upgrade
Receivables
0.90.720.49100.97
Upgrade
Other Current Assets
6.888.8117.65.7711.82
Upgrade
Total Current Assets
136.36199.11161.75105.56193.67
Upgrade
Property, Plant & Equipment
14.613.7829.3341.539.57
Upgrade
Long-Term Investments
8.211.9813.7200
Upgrade
Goodwill and Intangibles
0.40.732.051.371.43
Upgrade
Other Long-Term Assets
0.2312.574.641.720.56
Upgrade
Total Long-Term Assets
23.4239.0649.7444.5941.56
Upgrade
Total Assets
159.78238.17211.5150.16235.23
Upgrade
Accounts Payable
25.380.651.140.792.04
Upgrade
Deferred Revenue
95.12139.0698.2684.1682.38
Upgrade
Current Debt
1.131.681.821.930
Upgrade
Other Current Liabilities
-71.64-81.73-65.25-44.06-57.49
Upgrade
Total Current Liabilities
49.9959.6635.9842.8326.93
Upgrade
Long-Term Debt
7.7223.287.298.590
Upgrade
Other Long-Term Liabilities
83.2194.7977.0654.3269.99
Upgrade
Total Long-Term Liabilities
90.93118.0784.3562.969.99
Upgrade
Total Liabilities
140.92177.74120.33105.7396.92
Upgrade
Total Debt
8.8624.969.1110.520
Upgrade
Debt Growth
-64.52%173.89%-13.37%--
Upgrade
Retained Earnings
-489.63-428.31-316.68-286.07-177.07
Upgrade
Shareholders' Equity
18.8660.4391.1744.43138.31
Upgrade
Net Cash / Debt
119.72164.62134.5579.28180.89
Upgrade
Net Cash / Debt Growth
-27.27%22.35%69.72%-56.17%75.29%
Upgrade
Net Cash Per Share
31.1756.1968.7845.71129.23
Upgrade
Working Capital
86.37139.44125.7762.74166.74
Upgrade
Book Value Per Share
4.9120.6346.6025.6198.82
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).